On-demand use of a phosphodiesterase type-5 inhibitor did not affect prostatic or urinary outcomes of therapy for BPH, a post hoc analysis of a large randomized trial showed.
Study identifies 11 gene mutations linked to aggressive prostate cancer
This is the largest prostate cancer study that examined the exome, according to the researchers, who believe their findings can potentially inform the makeup of panels used for genetic testing in prostate cancer.
How APPs can bridge the gap in urologist shortages
In this episode, Janelle Bunce, PA-C, highlights the role that advanced practice providers can play in filling the gaps created by the growing workforce shortages in urology.
Clinical navigators may improve genomic testing rates among Black patients with prostate cancer
Data showed that the proportion of Black patients referred for genomic testing increased from 19% to 58% after the implementation of the precision medicine navigator.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
FDA approves nedosiran for primary hyperoxaluria type 1
The approval is supported by findings from the phase 2 PHYOX2 trial and interim data from the phase 3 PHYOX3 extension study.
bpMRI-based AI model may enhance detection of recurrence in post-RT prostate cancer
"The reported bpMRI-based AI model detected the majority of locally recurrent prostate cancer after radiotherapy," the authors wrote in their study conclusion.
2 Clarke Drive Cranbury, NJ 08512